Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05384496 · ClinicalTrials.gov registry record · Phase 2
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
A Phase 2 study of Mucosal Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05384496 is a Phase 2 study of Mucosal Melanoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 153-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05384496, a Phase 2 study of Mucosal Melanoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before. The researchers think that a combination of axitinib and nivolumab may help people with this disease because both drugs target and block proteins that play a role in cancer cell survival and growth. The researchers think the drugs may be more effective if given in combination rather than on their own.
Conditions Studied
Interventions
- DRUG Nivolumab and/or Ipilimumab
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- DRUG axitinib
Study Locations (2)
New York
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05384496
The ClinicalTrials.gov registry entry for NCT05384496 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 12 other Mucosal Melanoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucosal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab and/or Ipilimumab is the first listed.
NCT05384496 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05384496 about?
NCT05384496 is a clinical study titled "Axitinib and Nivolumab for the Treatment of Mucosal Melanoma". The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before. The researchers think that a combination of axitinib and nivolumab may help...
What is the current status of trial NCT05384496?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-05-17. Estimated completion is 2027-05.
What conditions does trial NCT05384496 study?
This clinical trial studies the following conditions: Mucosal Melanoma.
What interventions are being tested in trial NCT05384496?
The interventions under investigation include: Nivolumab and/or Ipilimumab (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION), axitinib (DRUG).
Who is sponsoring clinical trial NCT05384496?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05384496 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucosal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.